Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo - Induction by tumor necrosis factor-alpha and lipopolysaccharide

被引:263
作者
Samad, F [1 ]
Yamamoto, K [1 ]
Loskutoff, DJ [1 ]
机构
[1] Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA
关键词
obesity; 3T3; cells; thrombosis; endotoxin; TNF-alpha;
D O I
10.1172/JCI118404
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Although elevated plasma plasminogen activator inhibitor 1 (PAI-1) is associated with obesity, very little is known about its tissue or cellular origin, or about the events that lead to increased PAI-1 levels under obese conditions. Since TNF-alpha is increased in rodents both during obesity and in response to endotoxin treatment, we examined the effects of these agents on PAI-1 gene expression in the adipose tissue of CB6 mice, In untreated mice, PAI-1 mRNA was detected in both mature adipocytes and in stromal vascular cells. Both TNF-alpha and endotoxin significantly increased PAI-1 mRNA in the adipose tissue, peaking at 3-8 h. In situ hybridization analysis of adipose tissue from untreated mice revealed a weak signal for PAI-1 mRNA only in the smooth muscle cells within the vascular wall, In contrast, after endotoxin or TNF-alpha treatment, PAI-1 mRNA also was detected in adipocytes and in adventitial cells of vessels. Endotoxin also induced PAI-1 in endothelial cells, while TNF-alpha. additionally induced it in smooth muscle cells. Mature 3T3-L1 adipocytes in culture also expressed PAI-1 mRNA, and its rate of synthesis was also upregulated by TNF-alpha. These studies suggest that the adipose tissue itself may be an important contributor to the elevated PAI-1 levels observed in the plasma under obese conditions.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 49 条
[41]  
SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884
[42]  
SPRENGERS ED, 1987, BLOOD, V69, P381
[43]  
SUNDELL IB, 1989, ATHEROSCLEROSIS, V80, P9
[44]   CHANGES IN FIBRINOLYTIC PARAMETERS IN MALE-PATIENTS WITH TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
TAKADA, Y ;
URANO, T ;
WATANABE, I ;
TAMINATO, A ;
YOSHIMI, T ;
TAKADA, A .
THROMBOSIS RESEARCH, 1993, 71 (05) :405-415
[45]   FAT DISTRIBUTION AND PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN NONDIABETIC OBESE WOMEN [J].
VAGUE, P ;
JUHANVAGUE, I ;
CHABERT, V ;
ALESSI, MC ;
ATLAN, C .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (09) :913-915
[46]  
VANHINSBERGH VWM, 1988, BLOOD, V72, P1467
[47]   THE CARDIOVASCULAR RISK FACTOR PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IS RELATED TO INSULIN-RESISTANCE [J].
VANLOON, BJP ;
KLUFT, C ;
RADDER, JK ;
BLANKENSTEIN, MA ;
MEINDERS, AE .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (08) :945-949
[48]   THE PLASMINOGEN-ACTIVATOR PLASMIN SYSTEM [J].
VASSALLI, JD ;
SAPPINO, AP ;
BELIN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (04) :1067-1072
[49]   QUANTITATION OF MESSENGER-RNA BY THE POLYMERASE CHAIN-REACTION [J].
WANG, AM ;
DOYLE, MV ;
MARK, DF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (24) :9717-9721